Open | - |
Close | - |
Volume / Avg. | 0 / 569.269K |
Day Range | - - - |
52 Wk Range | 1.160 - 3.880 |
Market Cap | $142.035M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 49 |
Short Interest | 1.79% |
Days to Cover | 1.72 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of I-MAB (NASDAQ: IMAB) through any online brokerage.
Other companies in I-MAB’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Zura Bio (NASDAQ:ZURA), Molecular Partners (NASDAQ:MOLN), CytomX Therapeutics (NASDAQ:CTMX) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for I-MAB (NASDAQ: IMAB) was reported by Piper Sandler on Monday, March 18, 2024. The analyst firm set a price target for 10.00 expecting IMAB to rise to within 12 months (a possible 468.18% upside). 14 analyst firms have reported ratings in the last year.
The stock price for I-MAB (NASDAQ: IMAB) is $1.76 last updated March 18, 2024 at 9:25 AM EDT.
There are no upcoming dividends for I-MAB.
I-MAB’s FY earnings are confirmed for Monday, April 1, 2024.
There is no upcoming split for I-MAB.
I-MAB is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.